Table 4 Clinical outcomes of patients with viral pneumonia according to empiric antibacterial therapy
| Â | Long course | Short course | Mixed infection |
|---|---|---|---|
(n = 67) | (n = 28) | (n = 79) | |
Instances of subsequent MDRO infection or colonization | 25/47 (53.2) | 4/19 (21.1)* | 20/53 (37.7) |
 MRSA colonization | 2/10 (20) | 0/7 (0) | 3/15 (20) |
 VRE colonization | 3/6 (50) | 1/4 (25) | 9/20 (45) |
 MDRO infection | 20/31 (64.5) | 3/8 (37.5) | 8/18 (44.4) |
Patients with subsequent MDRO infection or colonization | 16 (23.9) | 3 (10.7) | 16 (20.3) |
 MRSA colonization | 2 (3.0) | 0 (0) | 3 (3.8) |
 VRE colonization | 3 (4.5) | 1 (3.6) | 9 (11.4) |
 MDRO infection | 13 (19.4) | 3 (10.7) | 7 (8.9) |
Subsequent Clostridium difficile infection | 1 (1.5) | 0 (0) | 2 (2.5) |
In-hospital mortality | 8 (11.9) | 3 (10.7) | 23 (29.1)** |
 Non-ICU | 1/23 (4.3) | 0/11 (0) | 0/16 (0) |
 ICU (all) | 7/44 (15.9) | 3/17 (17.6) | 23/63 (36.5)** |
 ICU – oncology | 4/18 (22.2) | 2/5 (40) | 10/16 (62.5)** |
 ICU – nononcology | 3/26 (11.5) | 1/12 (8.3) | 13/47 (27.7) |
Hospital LOS (days) | 11 (7–25) | 8.5 (5–20) | 17 (8.5-28) *** |
ICU LOS (days) | 8.1 (4.9-17.9) | 4.2 (2.8-14.7)* | 12 (5.1-19.1) *** |
Readmit within | |||
 30 days | 14 (20.9) | 4 (12.9) | 19 (24.0) |
 90 days | 22 (32.8) | 8 (25.8) | 27 (48.2) |
 180 days | 30 (44.8) | 11 (35.5) | 29 (51.8) |